Kribellosides, novel RNA 5'-triphosphatase inhibitors from the rare actinomycete Kribbella sp. MI481-42F6
- PMID: 28074052
- DOI: 10.1038/ja.2016.161
Kribellosides, novel RNA 5'-triphosphatase inhibitors from the rare actinomycete Kribbella sp. MI481-42F6
Abstract
Yeast capping enzymes differ greatly from those of mammalian, both structurally and mechanistically. Yeast-type capping enzyme repressors are therefore candidate antifungal drugs. The 5'-guanine-N7 cap structure of mRNAs are an essential feature of all eukaryotic organisms examined to date and is the first co-transcriptional modification of cellular pre-messenger RNA. Inhibitors of the RNA 5'-triphosphatase in yeast are likely to show fungicidal effects against pathogenic yeast such as Candida. We discovered a new RNA 5'-triphosphatase inhibitor, designated as the kribellosides, by screening metabolites from actinomycetes. Kribellosides belong to the alkyl glyceryl ethers. These novel compounds inhibit the activity of Cet1p (RNA 5'-triphosphatase) from Saccharomyces cerevisiae in vitro with IC50s of 5-8 μM and show antifungal activity with MICs ranging from 3.12 to 100 μg ml-1 against S. cerevisiae.
Similar articles
-
Nanomolar Inhibitors of Trypanosoma brucei RNA Triphosphatase.mBio. 2016 Feb 23;7(1):e00058-16. doi: 10.1128/mBio.00058-16. mBio. 2016. PMID: 26908574 Free PMC article.
-
Structure and mechanism of yeast RNA triphosphatase: an essential component of the mRNA capping apparatus.Cell. 1999 Nov 24;99(5):533-43. doi: 10.1016/s0092-8674(00)81541-x. Cell. 1999. PMID: 10589681
-
High-throughput assays for yeast RNA 5' triphosphatase (Cet1p).Anal Biochem. 2008 Jan 1;372(1):89-95. doi: 10.1016/j.ab.2007.07.016. Epub 2007 Jul 26. Anal Biochem. 2008. PMID: 17707331
-
The essential role for the RNA triphosphatase Cet1p in nuclear import of the mRNA capping enzyme Cet1p-Ceg1p complex of Saccharomyces cerevisiae.PLoS One. 2013 Oct 30;8(10):e78000. doi: 10.1371/journal.pone.0078000. eCollection 2013. PLoS One. 2013. PMID: 24205062 Free PMC article.
-
[Screening, characterization and pharmaceutical and medical application of enzyme inhibitors from microbial origin with low-molecular-weight].Yakugaku Zasshi. 1996 Jul;116(7):548-65. doi: 10.1248/yakushi1947.116.7_548. Yakugaku Zasshi. 1996. PMID: 8831259 Review. Japanese.
Cited by
-
Kribbellichelins A and B, Two New Antibiotics from Kribbella sp. CA-293567 with Activity against Several Human Pathogens.Molecules. 2022 Sep 26;27(19):6355. doi: 10.3390/molecules27196355. Molecules. 2022. PMID: 36234892 Free PMC article.
-
Marine Rare Actinomycetes: A Promising Source of Structurally Diverse and Unique Novel Natural Products.Mar Drugs. 2019 Apr 26;17(5):249. doi: 10.3390/md17050249. Mar Drugs. 2019. PMID: 31035452 Free PMC article. Review.
-
Therapeutic applications and biological activities of bacterial bioactive extracts.Arch Microbiol. 2021 Oct;203(8):4755-4776. doi: 10.1007/s00203-021-02505-1. Epub 2021 Aug 9. Arch Microbiol. 2021. PMID: 34370077 Free PMC article. Review.
-
Novel South African Rare Actinomycete Kribbella speibonae Strain SK5: A Prolific Producer of Hydroxamate Siderophores Including New Dehydroxylated Congeners.Molecules. 2020 Jun 29;25(13):2979. doi: 10.3390/molecules25132979. Molecules. 2020. PMID: 32610457 Free PMC article.
-
Secondary Metabolites of Actinomycetes and their Antibacterial, Antifungal and Antiviral Properties.Pol J Microbiol. 2018;67(3):259-272. doi: 10.21307/pjm-2018-048. Pol J Microbiol. 2018. PMID: 30451442 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous
